Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Predictive accuracy of gait speed for falls: An individual participant data meta-analysis.

Ageing research reviews·2026

Same author

Filtered-phase imaging versus susceptibility-weighted imaging for paramagnetic rim lesion detection in multiple sclerosis: A head-to-head comparison.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Same author

Industry Payments to Physicians Alter the Care of Patients With Multiple Sclerosis: It's Time to Cut Financial Ties.

Neurology·2026

Same author

Stop the Spin: Confronting Reporting Bias in Multiple Sclerosis Research.

Annals of neurology·2026

Same author

Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.

Neurology·2025

Same author

Late-Onset Multiple Sclerosis: Is Disease-Modifying Therapy Indicated?

Neurology·2025

Same journal

The need for another tool: Australian healthcare professionals on the use of psilocybin for existential distress in people with cancer.

BMC medicine·2026

Same journal

Liquid biopsy-based multi-omics approach for early detection of hepatocellular carcinoma (ASCEND-Hep): a multiphase prospective development and validation study.

BMC medicine·2026

Same journal

Effect of endoscopic screening for non-cardia gastric cancer: a 12-year report of a population-based randomized trial.

BMC medicine·2026

Same journal

Therapeutic activation of PPARα contributes to NOTCH1 inhibition in T-cell acute lymphoblastic leukemia.

BMC medicine·2026

Same journal

Social vulnerability index and inflammation: a proteomic analysis linking social context to biological risk in older black adults.

BMC medicine·2026

Same journal

Efficacy of remote ischemic conditioning on cerebral blood flow regulation in patients with endovascular stenting: a randomized controlled trial.

BMC medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Recent developments in multiple sclerosis therapeutics.

Rebecca I Spain¹, Michelle H Cameron, Dennis Bourdette

¹Oregon Health & Science University, Department of Neurology, CR120, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA. spainr@ohsu.edu

|December 9, 2009

Summary

This summary is machine-generated.

Multiple sclerosis (MS) treatments focus on inflammation in early stages but neurodegeneration dominates later. New therapies aim to target specific MS pathologies for better outcomes.

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

Related Experiment Videos

Last Updated: Jun 18, 2026

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

Area of Science:

Neurology
Immunology
Neuroscience

Background:

Multiple sclerosis is a common neurologic disorder in young adults.
Traditionally viewed as an inflammatory, autoimmune, demyelinating CNS disease.
Current therapies (corticosteroids, interferon-beta, glatiramer acetate, natalizumab) offer moderate effectiveness.

Purpose of the Study:

To review the evolving understanding of multiple sclerosis pathology.
To discuss current and emerging therapeutic strategies for different MS stages.
To highlight the need for effective treatments for progressive multiple sclerosis.

Main Methods:

Review of existing literature on multiple sclerosis pathogenesis and treatment.
Analysis of therapeutic approaches for relapsing and progressive forms of MS.
Discussion of novel drug development targeting specific disease mechanisms.

Main Results:

Inflammatory pathology characterizes early relapsing MS.
Neurodegenerative pathology becomes dominant in later progressive MS.
Newer therapies for relapsing MS may offer improved efficacy and administration but carry higher risks.

Conclusions:

Therapeutic strategies are shifting to target distinct pathologies in early versus late MS.
Oral medications and monoclonal antibodies are being developed for relapsing MS.
Effective treatments for progressive multiple sclerosis remain a critical unmet need.